Drugs for Parkinon’s disease
description
Transcript of Drugs for Parkinon’s disease
Drugs for Parkinon’s disease• Parkinson's disease
– progressive tremor– Bradykinesia and rigidity
– degeneration of the dopaminergic nigrostriatal pathway
– decrease in the striatal concentration of dopamine
– presence of Lewy bodies
• Degeneration of the nigrostriatal pathway leads to the depletion of the neurotransmitter dopamine
• therapy involved the administration of its precursor levodopa or agents that mimic the action of dopamine
Drug Therapy• Decrease cholinergic activity within
Basal Ganglia– Activating Dopamine receptors in
Substantia Nigra feeding back to Cholinergic Cells in the striatum
– Antagonize Acetylcholine receptors
Antiparkinsonian Drugs • Symptomatic Therapy
– The traditional approach to treating patients with Parkinson's disease is the administration of drugs to alleviate symptoms.
• Anticholinergic Agents and Amantadine • Levodopa • Synthetic Dopamine Agonists
Anticholinergic Agents
• Act by correcting the balance between dopamine and acetylcholine
• trihexyphenidyl and benztropine• Antagonists at muscarinic receptors• raise the concentration of dopamine in the
synaptic cleft
Anticholinergic Agents
• adverse effects– impairment of memory and hallucinations– impaired ocular accommodation– dryness of the mouth– Constipation– urinary retention– vasodilatation
Amantadine
• resembles the anticholinergic drugs• appears to enhance synthesis, release, or
reuptake of dopamine from the surviving Nigral Neurons
• often results in some improvement in rigidity and bradykinesia.
• induce ankle edema and livedo reticularis
of the legs
Levodopa • the cornerstone of symptomatic therapy• decarboxylated to dopamine• usually administered with a peripheral
decarboxylase inhibitor
L Dopa- Pharmacokinetics• L Dopa is readily absorbed from GI Tract• Large amount of L Dopa has to be given due to
First Pass Effect • L Dopa metabolized by dopa decarboxylase in
liver and periphery to dopamine• Secreted in urine unchanged or conjugated with
glucoronyl sulfate• Most of L Dopa converted to NE and EPI
Effects of L Dopa on the Symptoms of Parkinson Disease
• L Dopa fairly effective in eliminating most of the symptoms of Parkinson Disease
• Bradykinesia and rigidity respond quickly• Reduction in tremor effect with continued
therapy• L Dopa less effective in eliminating
postural instability and shuffling gait
Effects of L Dopa on Behavior
• L Dopa partially changes mood by elevating mood
• L Dopa increases patient sense of well being
Effects of L Dopa on Cardiovascular System• cardiac stimulation due to beta adrenergic
effect on heart• Elderly- transient tachycardia, cardiac
arrhythmias and hypertension
Effects of L Dopa on Gastrointestinal System
• Nausea, Vomiting, and Anorexia• Abdominal Pain• Diarrhea and Constipation• May cause activation of Peptic Ulcer
Synthetic Dopamine Agonists
• mimic the effect of dopamine by binding directly with the post-synaptic dopamine receptors
• Bromocriptine, pergolide and lisuride• tetracyclic ergot derivatives• longer plasma half-lives
Synthetic Dopamine Agonists
• The nonergot dopamine agonists ropinirole and pramipexole
• higher doses, they produce similar side effects
Protective Therapy • treat the underlying pathogenesis of
Parkinson's disease so that neurodegeneration is prevented or delayed
• Possible mechanisms of cell damage :– Autoimmunity– excessive excitatory drive– disturbance of trophic factors– increase in the concentration of toxic free
radicals
Protective Therapy• vitamins• co-enzyme Q10• dopamine agonists• monoamine oxidase type B (MAOB)
inhibitors.
Management of Different Stages of Disease
• Newly Diagnosed Parkinson's Disease – Hoehn-Yahr stage I– the patient has minor symptoms that are not
sufficiently troublesome to affect routine daily activities
– selegiline, levodopa, or a synthetic dopamine agonist or no pharmacotherapy
• National Collaborating Centre for Chronic Conditions. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006.
Levodopa
Dopamine Agonist
Monoamine oxidase type B(MAOB) inhibitors
ono
Beta Adrenergic agents
Amantadine
Anticholinergics
Severe Parkinson's Disease
• Management is directed toward decreasing the dose of the drug causing the most troublesome side effects and raising the dose of an alternative drug
Levodopa
Dopamine agonist
MOAB inhibitors
COMT
Amantadine
Management of Adverse Reactions to Therapy
• nausea and hypotension– associated with peak plasma concentrations
of dopaminomimetic agent– minimized by taking the medications after light
meals or snacks.– Domperidone 10 to 20 mg
Management of Adverse Reactions to Therapy
• Hypotension– increased intake of water and salt– fludrocortisone 0.1 mg once or bid– midodrine 2.5 to 20 mg
Management of Adverse Reactions to Therapy• Dyskinesia, fluctuations in mobility
– unpredictable "on-off" reactions– predictable "wearing-off" effects– Avoid high protein meals
Management of Adverse Reactions to Therapy• Psychiatric side effects
– confusion, visual hallucinations, and paranoia– begin as nocturnal phenomena– Neuroleptic drugs in general are
contraindicated
Thank you
Calne D. N Engl J Med 1993;329:1021-1027
Structure of the Dopamine D2A Receptor
Calne D. N Engl J Med 1993;329:1021-1027
Dopamine D1A Receptor Coupled to a G Protein and Linked to Adenylate Cyclase in a Striatal Neuron
Calne D. N Engl J Med 1993;329:1021-1027
Dopamine D1A Receptor Coupled to a G Protein and Linked to Adenylate Cyclase in a Striatal Neuron
Agents that Increase Dopamine functions• Increasing the synthesis of dopamine - l-Dopa• Inhibiting the catabolism of dopamine -
selegiline• Stimulating the dopamine receptor sites
directly - bromocriptine & pramipexole• Blocking the uptake and enhancing the release
of dopamine - amantadine